CBNK SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES CAPITAL BANCORP, INC.

Ademi LLP is investigating Peoples Bancorp's proposed all-stock acquisition of Capital (NASDAQ: CBNK), valued at approximately $728.1 million, under which Capital shareholders would receive stock worth about $43.75 per share. The law firm is scrutinizing the exchange ratio, insider change-of-control benefits, a potentially deterrent termination fee, and whether Capital's board adequately protected shareholder interests. The investigation could increase transaction-related legal and governance risk, though it does not itself indicate that the deal will be blocked or repriced.

Analysis

The legal inquiry is not, by itself, evidence of a deal defect; these announcements are commonly solicitation-driven and rarely alter closing economics absent a credible competing bid, material process disclosure failure, or a financing/regulatory surprise. The near-term implication is modestly higher CBNK deal-spread volatility, not a fundamental repricing. The actionable variable is the implied spread to the fixed stock consideration after adjusting for PEBO’s share-price movement, expected closing date, and dividend treatment—none of which is supplied here.

For PEBO, the more relevant 1-3 month risk is that shareholder-litigation headlines raise transaction costs or force incremental disclosure, while the economic risk remains acquisition-related: stock issuance can pressure the acquirer if investors assign a lower multiple to pro forma credit exposure, cost-save execution, or capital ratios. Over 6-18 months, a successful integration could be accretive if deposit retention and expense saves exceed underwriting assumptions; failure would show up first through elevated deposit betas, higher merger charges, or weaker-than-guided tangible-book-value earnback.

Consensus is likely to overread the headline as a litigation catalyst. Unless a rival bidder emerges or the investigation produces a specific claim tied to undisclosed banker conflicts or an unusually restrictive deal-protection package, the expected-value impact is de minimis. The more interesting setup is event-driven: a widening CBNK spread caused by retail concern could create a favorable risk-adjusted merger-arbitrage entry, but only after validating regulatory approvals, termination fee, exchange mechanics, and PEBO borrow/liquidity.

Key Decisions for Investors

• Do not treat the law-firm announcement as a standalone CBNK short signal; maintain no directional position until the live CBNK price, PEBO exchange ratio, expected close date, and regulatory conditions permit calculation of annualized spread return.
• Set an alert for a CBNK implied deal spread wider than 5-7% on no new regulatory or financing development. If the transaction documentation shows standard conditions and a sub-9-month close, consider long CBNK / short the appropriate PEBO share equivalent as a hedged merger-arbitrage position; target 10-15% annualized return, with exit on a material adverse credit development or deal termination.
• Monitor PEBO’s next earnings release for tangible common equity dilution, expected cost saves, deposit attrition, and credit marks attributable to the transaction. A guidance reset on any of these items would favor a 1-3 month PEBO underweight versus KRE rather than an unhedged short.
• Treat a revised bid, a disclosed superior-proposal process, or a court action seeking to enjoin the vote as upside catalysts for CBNK and risks to a hedged arbitrage short leg; reassess immediately if the spread compresses below roughly 2%, where residual closing risk is unlikely to be adequately compensated.